ELI LILLY & Co

LLY

ELI LILLY & Co

LLY

Insider Sentiment (TTM):

Last Purchase:2025-08-15Last Sale:2026-06-10Shares Purchased (TTM):6,987Shares Sold (TTM):3,400,282

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:733,100,019Shares Outstanding:894,500,000Institutional Ownership Pct.:81.96%

Earnings Market Reaction:

Filing Date:2026-04-30Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

JNJ ABBV MRK ABT PFE BMY

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	5,282	7,268	9,792	3,376	3,093	3,268	3,369	3,224	2,460	2,819	2,381	2,695
Short Term Investments	-	-	122	170	127	155	149	140	126	109	113	135
Accounts Receivable Net Current	18,429	17,760	16,107	14,170	12,037	11,006	10,295	11,028	7,886	9,091	8,167	7,516
Other Receivables Net Current	2,748	2,395	3,350	3,035	1,967	2,270	1,757	2,051	2,128	2,246	2,197	1,655
Inventory Net	14,529	13,744	12,180	11,014	9,311	7,589	7,460	6,482	6,102	5,773	4,901	4,799
Prepaid Expense And Other Assets Current	-	-	-	-	-	-	-	-	-	-	5,248	4,532
Prepaid Expense Current	13,633	14,315	20,249	18,020	14,654	8,341	8,251	7,138	6,349	5,541	-	-
Other Assets Current	214	147	272	69	72	266	135	142	139	150	-	-
Assets Current	54,835	55,629	62,071	49,854	41,261	32,740	31,415	30,204	25,189	25,727	23,007	21,332
Assets Noncurrent
Long Term Investments	3,116	2,802	2,808	3,207	3,223	3,216	3,200	2,878	3,087	3,052	2,692	2,745
Goodwill	6,130	5,898	5,898	5,771	5,771	5,770	5,768	5,768	4,940	4,940	4,085	4,079
Intangible Assets Net Excluding Goodwill	7,374	6,521	6,447	5,908	6,012	6,166	6,537	6,636	6,762	6,907	6,782	6,904
Deferred Income Tax Assets Net	11,350	9,959	8,963	9,427	8,573	8,001	7,392	6,655	5,634	5,477	4,575	3,806
Property Plant And Equipment Net	26,540	24,675	22,316	20,530	18,474	17,102	16,172	14,829	13,624	12,914	11,863	11,277
Other Assets Noncurrent	7,231	6,992	6,432	6,225	6,075	5,720	5,122	4,904	4,708	4,990	4,912	4,672
Assets	116,576	112,476	114,935	100,923	89,389	78,715	75,607	71,875	63,944	64,006	57,916	54,814
Liabilities And Stockhold…
Liabilities Current
Debt Current	4,000	1,635	1,633	5,724	4,016	5,117	2,074	5,162	1,652	6,905	2,245	662
Accounts Payable Current	5,029	5,379	4,262	4,076	3,442	3,229	2,887	2,925	2,474	2,599	2,435	2,474
Employee Related Liabilities Current	1,359	2,375	1,966	1,303	1,114	2,094	1,703	1,168	844	1,650	1,233	868
Dividends Payable Current	-	-	-	1,345	0	1,346	0	1,171	0	1,169	0	1,016
Taxes Payable Current	-	-	9,444	6,958	6,176	-	-	-	-	-	1,978	1,234
Other Liabilities Current	8,699	8,457	5,215	5,077	3,770	6,397	5,580	4,249	4,199	3,281	2,585	2,272
Liabilities Current	36,634	35,228	40,141	39,020	30,068	28,376	24,674	27,121	18,598	27,293	21,998	18,915
Long Term Debt Noncurrent	39,370	40,868	40,874	34,180	34,500	28,527	29,045	23,730	24,560	18,321	17,924	18,158
Pension And Other Postretirement Defined Benefit P…	-	-	-	1,345	1,316	1,301	1,449	1,420	1,428	1,439	1,312	1,309
Accrued Income Taxes Noncurrent	5,289	5,875	6,294	5,684	5,371	4,061	3,879	3,497	4,189	3,849	3,468	3,331
Other Liabilities Noncurrent	4,085	3,970	3,777	2,345	2,288	3,479	2,239	2,471	2,271	2,241	1,906	1,952
Liabilities Noncurrent	48,744	50,713	50,944	43,554	43,474	36,067	36,612	31,118	32,448	25,849	24,610	24,750
Stockholders Equity Inclu…
Common Stock Value	590	590	591	592	593	592	594	594	594	594	594	594
Additional Paid In Capital Common Stock	6,921	7,346	7,232	7,089	6,910	7,439	7,340	7,214	7,010	7,250	7,160	6,949
Retained Earnings Accumulated Deficit	29,514	24,470	22,252	17,376	15,100	13,545	13,627	13,178	12,554	10,312	10,310	10,369
Common Stock Shares Held In Employee Trust	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013	-3,013
Accumulated Other Comprehensive Income Loss Net Of…	-2,833	-2,880	-3,206	-3,716	-3,775	-4,322	-4,275	-4,379	-4,300	-4,327	-3,785	-3,789
Treasury Stock Common Value	-	-	-63	-55	-50	-50	-33	-33	-33	-44	-45	-45
Other Additional Capital	19	22	-	-	-	31	-	-	-	-	-	-
Stockholders Equity	31,198	26,535	23,793	18,349	15,765	14,272	14,321	13,636	12,897	10,864	11,220	11,064
Minority Interest	-	-	58	76	82	80	81	74	85	92	87	86
Liabilities And Stockholders Equity	116,576	112,476	114,935	100,923	89,389	78,715	75,607	71,875	63,944	64,006	57,916	54,814
Allowance For Doubtful Accounts Receivable Current	-	-	22	16	16	15	16	14	14	15	13	14
Accumulated Depreciation Depletion And Amortizatio…	-	-	12,411	12,554	12,147	-	11,816	11,428	11,235	-	10,768	10,632
Common Stock Shares Authorized	-	3,200	-	-	-	3,200	-	-	-	3,200	-	-
Common Stock Shares Issued	-	945	-	-	-	948	-	-	-	950	-	-

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	14.15%	17.75%	26.38%	-	-	-	-	-	-	-	-	-
2025	-9.94%	-3.75%	-2.62%	14.56%	13.31%	29.09%	25.67%	27.06%	23.14%	-4.46%	-9.74%	-7.06%
2024	3.55%	13.35%	9.96%	13.73%	3.99%	5.75%	-11.52%	-9.19%	-14.16%	-6.18%	-15.53%	-15.28%
2023	-	-	-	7.04%	3.20%	7.64%	3.78%	-1.52%	8.52%	1.11%	0.77%	1.89%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	1.50	1.58	1.55	1.28	1.37	1.15	1.27	1.11	1.35	0.94	1.05	1.13
Quick Ratio	0.73	0.78	0.74	0.53	0.58	0.59	0.64	0.61	0.68	0.53	0.58	0.63
Working Capital	18.20B	20.40B	21.93B	10.83B	11.19B	4.36B	6.74B	3.08B	6.59B	-1.57B	1.01B	2.42B
Leverage & Debt
Debt to Equity	2.74	3.24	3.83	4.50	4.66	4.52	4.28	4.27	3.96	4.89	4.15	3.95
Debt Ratio	0.73	0.76	0.79	0.82	0.82	0.82	0.81	0.81	0.80	0.83	0.80	0.80
Efficiency & Turnover
Asset Turnover TTM	0.70	0.68	0.62	0.62	0.64	0.63	0.61	0.61	0.61	0.60	0.61	0.58
Days Sales Outstanding TTM	76.96	80.54	81.09	86.35	74.19	81.42	82.45	86.95	78.28	85.50	84.68	85.83
Receivables Turnover TTM	4.74	4.53	4.50	4.23	4.92	4.48	4.43	4.20	4.66	4.27	4.31	4.25
Per Share Metrics
Diluted EPS TTM	28.21	22.95	20.48	15.34	12.33	11.71	9.25	8.12	6.79	5.80	5.54	7.20
Free Cash Flow Per Share TTM	22.90	18.74	17.91	12.18	10.37	9.79	6.70	5.01	4.08	4.71	6.54	5.89
Dividend Per Share TTM	6.24	6.00	5.80	5.60	5.40	5.20	5.03	4.86	4.69	4.52	4.37	4.23
Margin Metrics
Gross Profit Margin TTM	82.83%	83.04%	83.03%	82.64%	81.70%	81.31%	80.91%	80.75%	80.16%	79.25%	78.67%	77.77%
Operating Profit Margin TTM	43.08%	39.48%	37.87%	31.65%	27.75%	28.15%	24.84%	23.10%	21.04%	19.21%	19.15%	24.67%
Net Profit Margin TTM	34.99%	31.67%	30.99%	25.91%	22.66%	23.51%	20.48%	18.86%	17.08%	15.36%	15.55%	22.01%
Growth Metrics
Net Revenue Growth (1Y)	47.43%	44.70%	45.41%	36.83%	36.38%	32.00%	27.41%	31.87%	29.76%	19.56%	9.69%	1.53%
Net Income Growth (1Y)	127.60%	94.90%	119.98%	87.95%	80.93%	102.08%	67.79%	13.00%	7.94%	-16.08%	-17.32%	14.16%
EPS Growth (1Y)	128.66%	95.62%	120.98%	88.58%	81.35%	101.99%	67.56%	12.85%	7.97%	-15.94%	-17.23%	14.24%
Valuation Metrics
P/E TTM	32.49	46.56	36.99	50.37	66.23	64.95	94.19	109.56	112.40	98.41	95.05	63.57
P/B TTM	26.33	36.22	28.62	37.88	46.66	48.19	55.05	58.99	53.50	47.47	42.26	37.33
P/S TTM	11.37	14.74	11.46	13.05	15.01	15.27	19.29	20.67	19.20	15.11	14.78	13.99
Market Cap	821.32B	961.05B	681.02B	695.02B	735.52B	687.78B	788.34B	804.42B	689.96B	515.72B	474.13B	413.04B
Enterprise Value	859.41B	996.28B	713.73B	731.55B	770.95B	718.16B	816.09B	830.09B	713.71B	538.13B	491.92B	429.17B
Calculated Values
Free Cash Flow TTM	20.48B	16.81B	16.06B	10.94B	9.32B	8.82B	6.03B	4.51B	3.68B	4.24B	5.89B	5.30B
Net Debt	38.09B	35.24B	32.71B	36.53B	35.42B	30.38B	27.75B	25.67B	23.75B	22.41B	17.79B	16.13B
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Insider Transactions

2026-06-10Sale

Owner: Yuffa, Ilya

Title: EVP&Pres, LLY USA&Global Capab

Shares: 2,500

Price/Share: $1150.77

Value: $2,876,925.00

Shares Owned: 29,804

Relationship: Officer

Ownership: Direct

2026-05-06Sale

Owner: Lilly, Endowment Inc

Title: -

Shares: 15,828

Price/Share: $995.70

Value: $15,759,939.60

Shares Owned: 91,881,150

Relationship: Other

Ownership: Direct

2026-01-07Sale

Owner: Lilly, Endowment Inc

Title: -

Shares: 292,148

Price/Share: $1101.51

Value: $321,803,943.48

Shares Owned: 91,896,978

Relationship: TenPercentOwner

Ownership: Direct

2026-01-05Sale

Owner: Lilly, Endowment Inc

Title: -

Shares: 1,390

Price/Share: $1085.01

Value: $1,508,163.90

Shares Owned: 92,189,126

Relationship: TenPercentOwner

Ownership: Direct

2025-12-29Sale

Owner: Lilly, Endowment Inc

Title: -

Shares: 3,593

Price/Share: $1085.04

Value: $3,898,548.72

Shares Owned: 92,190,516

Relationship: TenPercentOwner

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-10	Yuffa, Ilya	Officer	EVP&Pres, LLY USA&Global Capab	Direct	Sale	2,500	1150.77	$2,876,925.00	29,804	4
2026-05-06	Lilly, Endowment Inc	Other	-	Direct	Sale	15,828	995.70	$15,759,939.60	91,881,150	4
2026-01-07	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	292,148	1101.51	$321,803,943.48	91,896,978	4
2026-01-05	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	1,390	1085.01	$1,508,163.90	92,189,126	4
2025-12-29	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	3,593	1085.04	$3,898,548.72	92,190,516	4
2025-12-24	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	2,629	1085.17	$2,852,911.93	92,194,109	4
2025-12-23	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	240	1085.04	$260,409.60	92,196,738	4
2025-11-25	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	15,632	1109.56	$17,344,641.92	92,196,978	4
2025-11-24	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	142,307	1070.96	$152,405,104.72	92,359,671	4
2025-11-21	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	105,326	1058.46	$111,483,357.96	92,501,978	4
2025-11-20	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	37,148	1052.95	$39,114,986.60	92,607,304	4
2025-11-19	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	167,526	1052.87	$176,383,099.62	92,644,452	4
2025-11-18	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	60,213	1035.01	$62,321,057.13	92,811,978	4
2025-11-17	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	9,886	1030.99	$10,192,367.14	92,872,191	4
2025-11-14	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	178,295	516449.12	$92,080,295,850.40	92,882,077	4
2025-11-13	Zakrowski, Donald A	Officer	SVP, Finance, & CAO	Direct	Sale	1,000	1010.50	$1,010,500.00	2,840	4
2025-11-13	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	46,606	1030.99	$48,050,319.94	93,060,372	4
2025-11-12	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	305,000	1011.53	$308,516,650.00	93,106,978	4
2025-11-11	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	283,131	985.92	$279,144,515.52	93,411,978	4
2025-11-10	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	16,869	973.30	$16,418,597.70	93,695,109	4
2025-11-05	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	40,432	951.34	$38,464,578.88	93,711,978	4
2025-11-04	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	526	910.72	$479,038.72	93,931,452	4
2025-11-03	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	300,000	889.35	$266,805,000.00	93,931,978	4
2025-10-31	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	301,342	866.02	$260,968,198.84	94,231,978	4
2025-10-10	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	3,658	862.86	$3,156,341.88	94,533,320	4
2025-10-09	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	10,602	852.81	$9,041,491.62	94,536,978	4
2025-10-08	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	101,420	852.10	$86,419,982.00	94,547,580	4
2025-10-07	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	26,795	848.01	$22,722,427.95	94,649,000	4
2025-10-06	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	161,183	852.07	$137,339,198.81	94,675,795	4
2025-10-03	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	192,404	834.94	$160,645,795.76	94,836,978	4
2025-10-02	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	112,596	826.99	$93,115,766.04	95,029,382	4
2025-10-01	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	215,822	820.94	$177,176,912.68	95,141,978	4
2025-09-30	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	113,694	764.76	$86,948,623.44	95,492,993	4
2025-09-19	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	23,665	763.76	$18,074,380.40	95,606,687	4
2025-09-18	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	106,626	765.38	$81,609,407.88	95,630,352	4
2025-08-28	Zakrowski, Donald A	Officer	SVP, Finance, & CAO	Direct	Sale	1,000	734.93	$734,930.00	3,840	4
2025-08-15	Montarce, Lucas	Officer	EVP & CFO	Direct	Purchase	715	691.79	$494,629.85	14,685	4
2025-08-13	Van, Naarden Jacob	Officer	EVP & Pres., Lilly Oncology	Direct	Purchase	1,000	647.36	$647,360.00	20,562	4
2025-08-13	Alvarez, Ralph	Director	-	Indirect	Purchase	758	660.25	$500,469.50	758	4
2025-08-12	Skovronsky, Daniel	Officer	EVP, CSO & Pres. LRL & LLY Imm	Direct	Purchase	1,000	634.41	$634,410.00	137,660	4
2025-08-12	Sulzberger, Gabrielle	Director	-	Direct	Purchase	117	641.18	$75,018.06	2,703	4
2025-08-12	Ricks, David A	Director,Officer	President, Chair, and CEO	Direct	Purchase	1,632	644.77	$1,052,264.64	546,601	4
2025-08-12	Fyrwald, J Erik	Director	-	Direct	Purchase	1,565	642.30	$1,005,199.50	74,578	4
2025-08-11	Yuffa, Ilya	Officer	EVP&Pres, LLY USA&Global Capab	Direct	Sale	1,250	627.01	$783,762.50	26,260	4
2025-08-08	Jackson, Jamere	Director	-	Direct	Purchase	200	639.56	$127,912.00	9,402	4
2025-07-24	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	280,000	805.95	$225,666,000.00	95,736,978	4
2025-05-27	Zakrowski, Donald A	Officer	SVP, Finance, & CAO	Direct	Sale	1,000	716.41	$716,410.00	4,840	4
2025-05-14	Yuffa, Ilya	Officer	EVP & President, LLY Int'l	Direct	Sale	1,250	749.24	$936,550.00	27,510	4
2025-03-13	Zakrowski, Donald A	Officer	SVP, Finance, & CAO	Direct	Sale	1,000	818.24	$818,240.00	5,840	4
2025-03-03	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	220,000	928.71	$204,316,200.00	96,016,978	4
2025-02-25	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	225,000	905.96	$203,841,000.00	96,236,978	4
2025-02-24	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	60,432	59386.22	$3,588,828,047.04	96,461,978	4
2025-02-21	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	99,452	885.59	$88,073,696.68	96,522,410	4
2025-02-20	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	14,685	878.84	$12,905,765.40	96,621,862	4
2025-02-19	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	9,985	878.96	$8,776,415.60	96,636,547	4
2025-02-13	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	35,446	880.55	$31,211,975.30	96,646,532	4
2025-02-10	Skovronsky, Daniel	Officer	EVP, CSO & Pres. LRL & LLY Imm	Direct	Sale	5,000	864.14	$4,320,700.00	117,888	4
2025-02-06	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	210,000	876.89	$184,146,900.00	96,681,978	4
2024-11-08	Zakrowski, Donald A	Officer	SVP, Finance, & CAO	Direct	Sale	900	803.38	$723,042.00	5,480	4
2024-09-03	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	24,084	967.74	$23,307,050.16	96,891,978	4
2024-08-27	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	24,552	969.44	$23,801,690.88	96,916,062	4
2024-08-26	Zakrowski, Donald A	Officer	SVP, Finance, & CAO	Direct	Sale	750	950.00	$712,500.00	6,380	4
2024-08-22	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	3,196	966.64	$3,089,381.44	96,940,614	4
2024-07-10	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	210,000	940.99	$197,607,900.00	96,943,810	4
2024-07-08	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	93,593	921.69	$86,263,732.17	97,153,810	4
2024-07-05	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	52,369	915.70	$47,954,293.30	97,247,403	4
2024-07-03	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	8,848	916.36	$8,107,953.28	97,299,772	4
2024-07-01	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	58,749	915.73	$53,798,221.77	97,308,620	4
2024-06-28	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	1,441	915.02	$1,318,543.82	97,367,369	4
2024-06-25	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	188,100	905.89	$170,397,909.00	97,368,810	4
2024-06-24	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	17,229	902.86	$15,555,374.94	97,556,910	4
2024-06-20	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	9,671	903.33	$8,736,104.43	97,574,139	4
2024-06-17	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	194,978	887.47	$173,037,125.66	97,583,810	4
2024-06-14	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	15,022	882.83	$13,261,872.26	97,778,788	4
2024-06-10	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	75,510	861.15	$65,025,436.50	97,793,810	4
2024-06-07	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	139,490	853.93	$119,114,695.70	97,869,320	4
2024-06-06	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	179,617	841.49	$151,145,909.33	98,008,810	4
2024-06-05	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	20,383	836.90	$17,058,532.70	98,188,427	4
2024-06-03	Norton, Johna	Officer	EVP, Global Quality	Direct	Sale	7,056	819.38	$5,781,545.28	25,428	4
2024-06-03	Zakrowski, Donald A	Officer	SVP, Finance, & CAO	Direct	Sale	750	819.47	$614,602.50	7,130	4
2024-06-03	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	192,794	830.28	$160,073,002.32	98,208,810	4
2024-05-31	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	22,206	822.63	$18,267,321.78	98,401,604	4
2024-05-29	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	130,385	812.44	$105,929,989.40	98,423,810	4
2024-05-28	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	2,052	809.00	$1,660,068.00	98,554,195	4
2024-05-24	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	92,563	809.21	$74,902,905.23	98,556,247	4
2024-05-23	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	50,767	812.27	$41,236,511.09	98,648,810	4
2024-05-22	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	12,974	804.18	$10,433,431.32	98,699,577	4
2024-05-21	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	186,259	808.57	$150,603,439.63	98,712,551	4
2024-03-11	Zakrowski, Donald A	Officer	SVP, Finance, & CAO	Direct	Sale	750	753.60	$565,200.00	7,880	4
2024-02-16	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	169,684	778.80	$132,149,899.20	98,898,810	4
2024-02-15	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	50,316	761.34	$38,307,583.44	99,068,494	4
2024-02-09	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	206,257	742.88	$153,224,200.16	99,118,810	4
2024-02-08	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	8,743	740.06	$6,470,344.58	99,325,067	4
2024-01-31	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	78,573	654.18	$51,400,885.14	99,333,810	4
2024-01-30	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	76,215	645.69	$49,211,263.35	99,412,383	4
2024-01-29	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	54,032	645.07	$34,854,422.24	99,488,598	4
2024-01-16	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	1,180	645.86	$762,114.80	99,542,630	4
2024-01-11	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	12,344	634.46	$7,831,774.24	99,543,810	4
2024-01-10	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	163,730	633.44	$103,713,131.20	99,556,154	4
2024-01-09	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	34,538	632.01	$21,828,361.38	99,719,884	4
2024-01-04	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	14,388	630.66	$9,073,936.08	99,754,422	4
2023-11-06	Zakrowski, Donald A	Officer	SVP, Finance, & CAO	Direct	Sale	670	571.10	$382,637.00	4,708	4
2023-10-11	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	215,000	605.51	$130,184,650.00	99,768,810	4
2023-09-12	Weems, Alonzo	Officer	EVP, ERM & CECO	Direct	Sale	1,148	590.98	$678,445.04	7,760	4
2023-09-07	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	210,000	570.22	$119,746,200.00	99,983,810	4
2023-08-31	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	46,541	555.88	$25,871,211.08	100,193,810	4
2023-08-30	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	6,181	555.74	$3,435,028.94	100,240,351	4
2023-08-29	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	28,747	554.96	$15,953,435.12	100,246,532	4
2023-08-28	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	37,660	277328.27	$10,444,182,648.20	100,275,279	4
2023-08-25	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	63,572	555.22	$35,296,445.84	100,312,939	4
2023-08-24	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	20,992	555.47	$11,660,426.24	100,376,511	4
2023-08-23	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	1,307	555.69	$726,286.83	100,397,503	4
2023-08-21	Zakrowski, Donald A	Officer	SVP, Finance, & CAO	Direct	Sale	600	546.51	$327,906.00	5,378	4
2023-08-15	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	50,222	542.80	$27,260,501.60	100,398,810	4
2023-08-14	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	164,778	540.40	$89,046,031.20	100,449,032	4
2023-08-11	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	83,039	529.82	$43,995,722.98	100,613,810	4
2023-08-10	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	3,000	528.14	$1,584,420.00	100,696,849	4
2023-08-09	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	123,961	530.36	$65,743,955.96	100,699,849	4
2023-08-08	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	204,409	521.62	$106,623,822.58	100,823,810	4
2023-07-21	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	591	466.62	$275,772.42	101,028,219	4
2023-06-30	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	164,125	467.46	$76,721,872.50	101,028,810	4
2023-06-29	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	44,115	465.08	$20,517,004.20	101,192,935	4
2023-06-28	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	11,760	465.78	$5,477,572.80	101,237,050	4
2023-06-22	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	107,022	458.99	$49,122,027.78	101,248,810	4
2023-06-21	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	31,454	454.54	$14,297,101.16	101,355,832	4
2023-06-20	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	34,156	454.08	$15,509,556.48	101,387,286	4
2023-06-16	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	25,015	455.53	$11,395,082.95	101,421,442	4
2023-06-15	Norton, Johna	Officer	EVP, Global Quality	Direct	Sale	1,647	448.00	$737,856.00	30,114	4
2023-06-15	Lilly, Endowment Inc	TenPercentOwner	-	Direct	Sale	27,353	454.59	$12,434,400.27	101,446,457	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Institutional Ownership

No data available for chart

2026-03-31

81.96%

Inst. Shares: 733,100,019

Shares Outstanding: 894,500,000

2025-12-31

83.94%

Inst. Shares: 753,154,648

Shares Outstanding: 897,300,000

2025-09-30

81.89%

Inst. Shares: 734,429,078

Shares Outstanding: 896,900,000

2025-06-30

83.02%

Inst. Shares: 745,394,734

Shares Outstanding: 897,900,000

2025-03-31

81.62%

Inst. Shares: 733,495,042

Shares Outstanding: 898,700,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	733,100,019	894,500,000	81.96%
2025-12-31	753,154,648	897,300,000	83.94%
2025-09-30	734,429,078	896,900,000	81.89%
2025-06-30	745,394,734	897,900,000	83.02%
2025-03-31	733,495,042	898,700,000	81.62%
2024-12-31	739,590,077	900,600,000	82.12%
2024-09-30	725,782,670	901,000,000	80.55%
2024-06-30	739,048,716	900,900,000	82.03%
2024-03-31	721,795,678	900,800,000	80.13%
2023-12-31	732,787,327	900,181,000	81.40%
2023-09-30	704,155,843	899,800,000	78.26%
2023-06-30	697,737,956	899,700,000	77.55%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

ELI LILLY & Co (LLY) — SEC Financial Statements & Analysis

ELI LILLY & Co (LLY) is a pharmaceutical preparations company, incorporated in IN. ELI LILLY & Co trades on LLY: NYSE as: LLY. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), ELI LILLY & Co reported a 47.43% year-over-year revenue growth, a Gross Profit Margin of 82.83% (TTM), a Debt-to-Equity ratio of 2.74x, a Price-to-Sales (P/S) ratio of 11.37x (TTM), a Price-to-Book (P/B) ratio of 26.33 (TTM), at a market cap of $821.32B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 47.43%
Gross Profit Margin TTM: 82.83%
Debt To Equity: 2.74x
P/S TTM: 11.37x
P/B TTM: 26.33
Market Cap: $821.32B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ELI LILLY & Co in?

ELI LILLY & Co (LLY) operates in the Pharmaceutical Preparations industry.

What is LLY's market cap?

ELI LILLY & Co (LLY) has a market capitalization of $821.32B as of 2026-03-31.

What is LLY's P/E ratio?

ELI LILLY & Co (LLY)'s trailing twelve month P/E ratio is 32.49x as of 2026-03-31.

What exchange does LLY trade on?

ELI LILLY & Co (LLY) trades on the LLY: NYSE.

Where is ELI LILLY & Co incorporated?

ELI LILLY & Co is incorporated in IN.

ELI LILLY & Co (LLY) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.